

October 23, 2017

To,
SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589.

Dear Sir/Madam

Sub:- Board Meeting

We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday, November 2, 2017, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Second Quarter and Half year ended September 30, 2017.

Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from September 25, 2017 to November 6, 2017 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Second Quarter and Half year ended September 30, 2017.

The above is for your information.

Thanking you.

Yours faithfully,
For Glenmark Pharmaceuticals Limited



Harish Kuber
Company Secretary & Compliance Officer
Tel: 4018 9999 / 4018 9879
Fax: 4018 9986 (Legal & Secretarial Dept.)